Multiple Sclerosis
Multiple sclerosis is a common condition of young people and mature adults, affecting nearly a million Americans. The most common form is Relapsing-Remitting, but there are also Primary Progressive, Secondary Progressive, and Progressive-Relapsing subtypes. New trials are directed against the disease itself, hoping to slow progression, or against particular symptoms like spasticity (stiffness of muscles and limbs).
| Condition(s) | Type of Drug | Phase | Comparator | Duration | Open Label Extension |
|---|---|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | Higher dose of approved Ocrevus infusion | III | Regular dose Ocrevus | 2 years | 6 years |
| Primary Progressive Multiple Sclerosis | Higher dose of approved Ocrevus infusion | III | Regular dose Ocrevus | 2 years | 6 years |
| Relapsing-Remitting Multiple Sclerosis | Oral BKT inhibitor | III | Teriflunomide | 96 weeks | 96 weeks |
Response Form
If you or a loved one is interested in participating in one of our trials, please contact us at (855) 829-8899 or use the form below. One of our skilled Clinical Research Coordinators will contact you as soon as possible. Thank you for your interest in our research!
- Stephen S. Flitman, MD, Medical Director
